Architecture
Multimodal mixture-of-experts transformer
Enchant v3 is Iambic's multimodal transformer for drug discovery. It predicts molecular properties and preclinical and clinical endpoints from structures, sequences, omics, assay data, text and images, and Iambic uses it to choose compounds and prioritise experiments.
No reviewed evaluations are linked here in this release. See the sources below.
Multimodal mixture-of-experts transformer
limited source coverage · Automated source review, 2026-11-02. All specifications and missing details
Enchant v3 has no ranked result on a use-case protocol in this release.
Recorded parameters: 41 billion. Licence: Not recorded.
Deployment facts recorded for Enchant v3. Fields the record does not carry are marked not recorded.
Evaluated Checkpoint: Enchant v3 (announced 21 September 2026)
A mixture-of-experts transformer trained jointly on many data types and endpoints, so that data on one endpoint or molecule informs predictions for related ones. Each prediction carries an uncertainty estimate, which Iambic uses to decide which experiments to run. The model is fine-tuned each week on new laboratory data.
Enchant v1 (2024) had 1 billion parameters and Enchant v2 (2025) 7 billion. Enchant v3 has 41 billion. New in v3: inverse design, omics-based and image-based prediction, and peptides. Results and access terms of v1 or v2 do not carry over to v3. NeuralPLexer is a separate Iambic model for protein-ligand structure.
Checked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md.
Stable record: enchant-v3-20261102-model-enchant-v3Explanatory profile: limited source coverage · Automated source review, 2026-11-02. Review applies to the cited claims; unresolved fields are listed below. Numerical results retain their own review status.
| Property | Description and evidence |
|---|---|
| Parameters | 41 billionSources (2)Enchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report); Iambic launches Enchant v3 (Iambic press release) · enchant-v3-20261102-source-report: 'Enchant v3: Achieving scalable predictability'; enchant-v3-20261102-source-release: highlights |
| Architecture | Multimodal mixture-of-experts transformerSourcesEnchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report) · enchant-v3-20261102-source-report: 'Enchant v3: Achieving scalable predictability' |
| Pretraining | 4.5 trillion tokensSourcesIambic launches Enchant v3 (Iambic press release) · enchant-v3-20261102-source-release: highlights |
| Prediction targets | More than 6,000 molecular propertiesSourcesIambic launches Enchant v3 (Iambic press release) · enchant-v3-20261102-source-release: subtitle and highlights |
| Input modalities | 16, including text, assay data, molecule, protein and 3D structure, images, multi-omics, biologics, clinical trial data and pharmacokineticsSourcesIambic launches Enchant v3 (Iambic press release) · enchant-v3-20261102-source-release: highlights |
| Training data | Public, proprietary and partner data; not itemised · Not reported in inspected sourcesSources (2)Enchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report); Iambic launches Enchant v3 (Iambic press release) · enchant-v3-20261102-source-report: 'Expand therapeutic opportunity'; enchant-v3-20261102-source-release: 'Ingest diverse data' |
| Weights, API and licence | None located; Iambic describes internal and partner deployment · Source unavailableSources (2)Enchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report); Iambic platform page · enchant-v3-20261102-source-report: 'Enchant drives an engine for new medicines'; enchant-v3-20261102-source-platform: platform description |
| Outputs | Not extracted or verified for this record. |
| Known versions | Not extracted or verified for this record. |
| Context limits | Not extracted or verified for this record. |
| Access | Not extracted or verified for this record. |
| Code licence | Not extracted or verified for this record. |
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
22 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Parameters 41 billion Individual claims | Iambic launches Enchant v3 (Iambic press release) enchant-v3-20261102-source-report: 'Enchant v3: Achieving scalable predictability'; enchant-v3-20261102-source-release: highlights Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Press release dated 21 September 2026, as served on 2026-11-02 | source checked automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Parameters 41 billion Individual claims | Enchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report) enchant-v3-20261102-source-report: 'Enchant v3: Achieving scalable predictability'; enchant-v3-20261102-source-release: highlights Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Web page dated 21 September 2026, as served on 2026-11-02 | source checked automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Architecture Multimodal mixture-of-experts transformer Individual claims | Enchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report) enchant-v3-20261102-source-report: 'Enchant v3: Achieving scalable predictability' Version: Web page dated 21 September 2026, as served on 2026-11-02 | source checked automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Pretraining 4.5 trillion tokens Individual claims | Iambic launches Enchant v3 (Iambic press release) enchant-v3-20261102-source-release: highlights Version: Press release dated 21 September 2026, as served on 2026-11-02 | source checked automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Prediction targets More than 6,000 molecular properties Individual claims | Iambic launches Enchant v3 (Iambic press release) enchant-v3-20261102-source-release: subtitle and highlights Version: Press release dated 21 September 2026, as served on 2026-11-02 | source checked automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Input modalities 16, including text, assay data, molecule, protein and 3D structure, images, multi-omics, biologics, clinical trial data and pharmacokinetics Individual claims | Iambic launches Enchant v3 (Iambic press release) enchant-v3-20261102-source-release: highlights Version: Press release dated 21 September 2026, as served on 2026-11-02 | source checked automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Training data Public, proprietary and partner data; not itemised Individual claims | Iambic launches Enchant v3 (Iambic press release) enchant-v3-20261102-source-report: 'Expand therapeutic opportunity'; enchant-v3-20261102-source-release: 'Ingest diverse data' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Press release dated 21 September 2026, as served on 2026-11-02 | unreported automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Training data Public, proprietary and partner data; not itemised Individual claims | Enchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report) enchant-v3-20261102-source-report: 'Expand therapeutic opportunity'; enchant-v3-20261102-source-release: 'Ingest diverse data' Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Web page dated 21 September 2026, as served on 2026-11-02 | unreported automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Weights, API and licence None located; Iambic describes internal and partner deployment Individual claims | Iambic platform page enchant-v3-20261102-source-report: 'Enchant drives an engine for new medicines'; enchant-v3-20261102-source-platform: platform description Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Web page as served on 2026-11-02 | unavailable automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Weights, API and licence None located; Iambic describes internal and partner deployment Individual claims | Enchant v3: Molecular superintelligence for end-to-end drug R&D (Iambic report) enchant-v3-20261102-source-report: 'Enchant drives an engine for new medicines'; enchant-v3-20261102-source-platform: platform description Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Web page dated 21 September 2026, as served on 2026-11-02 | unavailable automated source review · 2026-11-02 Audit detailsChecked against the three pinned Iambic pages; build.py asserts each quoted figure. See docs/reviews/2026-11-02-enchant-v3.md. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Release 2026-11-21-c8bea25e5abb · Record review: discovered
Technical metadata for this record is tracked under stable ID enchant-v3-20261102-model-enchant-v3.
Source locator: enchant-v3-20261102-source-report: whole report; enchant-v3-20261102-source-release: highlights; enchant-v3-20261102-source-platform: platform description
Enchant v3. Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/model/enchant-v3-20261102-model-enchant-v3/
Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.
The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence